AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16538941
Drug: Calamine lotion
RxNorm normalized name: CALAMINE LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calamine lotion
Trial: 11113407
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of propafenone (450 to 675 mg/day)
Trial: 11113407
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of propafenone with low-dose quinidine (150 mg/day)
Trial: 11113407
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of propafenone plus quinidine (600 mg/day)
Trial: 11113407
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (combination of all treatments)
Trial: 9082591
Drug: Intravascular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular laser therapy
Trial: 3888169
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg plus scopolamine 0.4 mg with d-amphetamine 10 mg
Trial: 3888169
Drug: scopolamine 1
RxNorm normalized name: scopolamine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine 1 mg with d-amphetamine 10 mg
Trial: 3888169
Drug: scopolamine 0.25
RxNorm normalized name: scopolamine 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine 0.25 mg
Trial: 3888169
Drug: scopolamine 0.5
RxNorm normalized name: scopolamine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine 0.5 mg
Trial: 3888169
Drug: scopolamine 0.6
RxNorm normalized name: scopolamine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine 0.6 mg
Trial: 3888169
Drug: marezine 50
RxNorm normalized name: Marezine 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: marezine 50 mg
Trial: 15945400
Drug: meclizine 50
RxNorm normalized name: meclizine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meclizine 50 mg
Trial: 15945400
Drug: dimenhydrinate 50
RxNorm normalized name: dimenhydrinate 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dimenhydrinate 50 mg
Trial: 3888169
Drug: scopolamine 1
RxNorm normalized name: scopolamine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine 1 mg with d-amphetamine 5 mg
Trial: 3888169
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg with d-amphetamine 10 mg
Trial: 3888169
Drug: scopolamine 1
RxNorm normalized name: scopolamine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine 1 mg
Trial: 3888169
Drug: scopolamine 0.8
RxNorm normalized name: scopolamine 0.86 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine 0.8 mg
Trial: 3888169
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg oral
Trial: 3888169
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg I.M.
Trial: 3888169
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg with scopolamine 0.4 mg
Trial: 3888169
Drug: promethazine 25
RxNorm normalized name: promethazine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 25 mg oral plus 25 mg I.M. with d-amphetamine 10 mg
Trial: 24943480
Drug: 5-hydroxytryptophan (5-HTP)
RxNorm normalized name: 5-hydroxytryptophan (5-HTP) 50 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (5-HTP) 100 mg
Trial: 22768457
Drug: Gonadotropin therapy
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin therapy
Trial: 20880898
Drug: Combined β
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined β blocker and behavioural migraine management
Trial: 20880898
Drug: β blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β blocker alone
Trial: 20880898
Drug: Optimised acute
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised acute treatment alone
Trial: 20880898
Drug: Optimised acute
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised acute treatment plus combined β blocker and behavioural migraine management
Trial: 27125273
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (hepatitis B)
Trial: 11255809
Drug: Actinomycin D
RxNorm normalized name: Actinomycin D
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Actinomycin D (one course administered within one week after evacuation of molar tissues)
Trial: 11255809
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intravenous fluid and analgesic drugs only)
Trial: 9825577
Drug: Consolidation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation therapy (after achieving complete remission)
Trial: 9825577
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no further therapy after complete remission)
Trial: 29510398
Drug: Intravenous Diacetylmorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Diacetylmorphine (DAM)
Trial: 23600965
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (physiotherapy + acupuncture)
Trial: 22005660
Drug: 4 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 × 15 mL of 0.25% bupivacaine
Trial: 2246657
Drug: Cyproheptadine (maximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (maximal dose 24 mg/day)
Trial: 2246657
Drug: Cyproheptadine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (administered for a minimum of six months at optimal dose)
Trial: 2246657
Drug: Cyproheptadine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine therapy
Trial: 31479159
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor treatment
Trial: 30784638
Drug: Active case
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active case finding strategy (combination of active and passive case finding)
Trial: 24754313
Drug: Eprotirome 100
RxNorm normalized name: Eprotirome
DrugBank: Eprotirome (DB05035)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprotirome 100 μg day(-1)
Trial: 24754313
Drug: Eprotirome 200
RxNorm normalized name: Eprotirome
DrugBank: Eprotirome (DB05035)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprotirome 200 μg day(-1)
Trial: 21312304
Drug: Testofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testofen (600 mg per day)
Trial: 19406557
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (two doses of 200mg iron sucrose)
Trial: 19406557
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (three doses of 200mg iron sucrose)
Trial: 19406557
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (daily 80 mg ferrous sulphate)
Trial: 9549575
Drug: Aspirin 1.2
RxNorm normalized name: Aspirin 1.2 GM Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1.2 g daily in 3 divided doses from 2 days before to 14 days after surgery
Trial: 9549575
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight dextran 500 ml, infused intravenously at 50 ml/hour during surgery and on each of the following 2 days
Trial: 8056005
Drug: Nifedipine (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (specific dosage not mentioned)
Trial: 2494249
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aqueous nasal spray, 400 micrograms daily
Trial: 2494249
Drug: Astemizole, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole, 10 mg daily
Trial: 2494249
Drug: Both trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both trial medications (beclomethasone and astemizole)
Trial: 29912983
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg fast-release melatonin
Trial: 28731485
Drug: Conventional comprehensive
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional comprehensive treatment plus high-volume hemofiltration (CBP group)
Trial: 28731485
Drug: Conventional comprehensive
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional comprehensive treatment only (non-CBP group), n = 11
Trial: 22171668
Drug: Self-tapping implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-tapping implants placed after bone condensing
Trial: 22171668
Drug: Non-self-tapping implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-self-tapping implants placed after bone condensing
Trial: 22171668
Drug: Self-tapping implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-tapping implants placed after bone drilling
Trial: 22171668
Drug: Non-self-tapping implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-self-tapping implants placed after bone drilling
Trial: 22171668
Drug: Both implant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both implant types placed after bone condensing
Trial: 22171668
Drug: Both implant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both implant types placed after bone drilling
Trial: 20873697
Drug: ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac tromethamine ophthalmic solution
Trial: 18566549
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized Japanese cedar extract, administered daily to once a week after six weeks.
Trial: 18566549
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered in the same manner as SLIT.
Trial: 18566549
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized Japanese cedar extract
Trial: 12918150
Drug: Oral Tegafur
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral Tegafur plus intravesical mitomycin
Trial: 6890537
Drug: Intradermal BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BCG
Trial: 6890537
Drug: Antigen G
RxNorm normalized name: Blood group antigen G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antigen G (soluble cytoplasmic components of M. piscium and M. balnei)
Trial: 31519504
Drug: Distractive video
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distractive video during local anesthetic administration
Trial: 28647677
Drug: Buprenorphine (2–4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (2–4 mg; sublingual)
Trial: 28647677
Drug: Placebo (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablets with identical shape, color, consistency, and scent)
Trial: 19139383
Drug: Rifalazil 25
RxNorm normalized name: Rifalazil
DrugBank: Rifalazil (DB04934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifalazil 25 mg once weekly for 8 weeks
Trial: 11755953
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg enoxaparin administered 12 hours before and 12 hours after surgery, then once daily for 7 days
Trial: 8457049
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 micrograms/ml with bupivacaine 0.01% and epinephrine 0.5 micrograms/ml
Trial: 8457049
Drug: Sufentanil 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.8 micrograms/ml with bupivacaine 0.01% and epinephrine 0.5 micrograms/ml
Trial: 27716690
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg loading dose over 15 min, maintained at 0.3 μg/kg/h)
Trial: 24249435
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day, 28 days on and 14 days off)
Trial: 22447964
Drug: Biomarker-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-directed therapy (prednisolone or matching placebo based on blood eosinophil count)
Trial: 22447964
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (prednisolone for 2 weeks)
Trial: 21083889
Drug: golimumab, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab, 100 mg plus placebo
Trial: 21083889
Drug: golimumab, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab, 50 mg plus MTX
Trial: 21083889
Drug: golimumab, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab, 100 mg plus MTX
Trial: 18771050
Drug: Pegylated interferon-alpha2b
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon-alpha2b (1.0 microg/kg/week) plus ribavirin (800-1,200 mg/day) for 48 weeks
Trial: 18771050
Drug: Recombinant interferon-alpha2b
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon-alpha2b (3 million IU three times/week) plus ribavirin (800-1,200 mg/day) for 48 weeks
Trial: 15645383
Drug: Peripheral nerve
RxNorm normalized name: Peripheral nerve antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral nerve blocks (PNB) with 20 ml bupivacaine 0.5 % + 60 ml prilocaine 1 %
Trial: 15645383
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia (EA) with 12 ‐ 20 ml bupivacaine 0.5 %
Trial: 8620704
Drug: Iodinated glycerol
RxNorm normalized name: iodinated glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodinated glycerol (IG) 60 mg qid for 16 weeks
Trial: 2013587
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (5000 international units once daily)
Trial: 2013587
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (5000 international units three times a day)
Trial: 18573149
Drug: Acid gel,
RxNorm normalized name: SALICYLIC ACID GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid gel, semi-gel, low-viscosity gel, liquid
Trial: 10793593
Drug: S(+)‐ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine 0.5 mg kg‐1 (group K1)
Trial: 10793593
Drug: S(+)‐ketamine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine 1.0 mg kg‐1 (group K2)
Trial: 1425626
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of ondansetron
Trial: 30016396
Drug: Daily remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily remote monitoring
Trial: 31359526
Drug: Compulsory community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compulsory community treatment
Trial: 17391302
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD) - 20 mg doxycycline twice daily
Trial: 16241013
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (500 mg) 2 hours before the procedure
Trial: 12463579
Drug: Fondaparinux (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux (administered not earlier than 6 hours postoperatively)
Trial: 7607964
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation (HF XRT) with chemotherapy, total radiation dose of 59.4 Gy, in 1.10 Gy fractions, twice daily at 6‐8 h intervals.
Trial: 7607964
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation (HF XRT) with chemotherapy
Trial: 31244293
Drug: Post-operative concurrent
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative concurrent chemoradiation (CCRT)
Trial: 28663317
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg prednisolone daily for 10 days
Trial: 22052139
Drug: RhG‐CSF administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RhG‐CSF administered as a subcutaneous single dose of 10 μg/kg
Trial: 22052139
Drug: RhG‐CSF administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RhG‐CSF administered as 10 μg/kg/s.c./day once daily for 3 days
Trial: 19536424
Drug: Tramiprosate 100
RxNorm normalized name: TRAMIPROSATE
DrugBank: Tramiprosate (DB06527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramiprosate 100 mg BID
Trial: 19536424
Drug: Tramiprosate 150
RxNorm normalized name: TRAMIPROSATE
DrugBank: Tramiprosate (DB06527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramiprosate 150 mg BID
Trial: 10558961
Drug: Combination hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination hepatitis A/hepatitis B vaccine (3 different manufacturing consistency lots)
Trial: 10558961
Drug: Combination hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination hepatitis A/hepatitis B vaccine
Trial: 10558961
Drug: Separate but
RxNorm normalized name: trans-but-2-enedioic acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate but concurrent injections of hepatitis A and hepatitis B vaccines
Trial: 6338856
Drug: Thioridazine hydrochloride
RxNorm normalized name: Thioridazine Hydrochloride
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine hydrochloride (during administration)
Trial: 30103529
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (IFA) supplements
Trial: 30103529
Drug: Medium-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-quantity lipid-based nutrient supplements (MQ-LNS)
Trial: 15242865
Drug: IFN beta
RxNorm normalized name: IFN beta2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta 2.2 microg (0.05 ml)
Trial: 15242865
Drug: IFN beta
RxNorm normalized name: IFN beta2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta 44 microg (0.5 ml)
Trial: 15242865
Drug: Placebo (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.05 ml or 0.5 ml)
Trial: 593192
Drug: gestonoroncapronate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gestonoroncapronate (600 mg/week)
Trial: 28928195
Drug: Baby mCIMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baby mCIMT (modified constraint‐induced movement therapy)
Trial: 28928195
Drug: Baby BIM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baby BIM (bimanual therapy)
Trial: 17229239
Drug: Histamine‐2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine‐2 receptor antagonists
Trial: 17229239
Drug: Alginate/antacid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate/antacid combination
Trial: 11689731
Drug: Walking activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking activity (3 km/d above daily lifestyle walking)
Trial: 9244939
Drug: 0.04% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04% bupivacaine plus adrenalin 1/2,500,000 and fentanyl 2.5 micrograms/ml (Group II)
Trial: 9244939
Drug: 0.0625% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625% bupivacaine plus adrenalin 1/1,600,000 and fentanyl 2 micrograms/ml (Group III)
Trial: 7706602
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg beta-carotene
Trial: 7706602
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg canthaxanthin
Trial: 7706602
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg beta-carotene and 25 mg canthaxanthin (combined dose)